Klin Farmakol Farm. 2011;25(2):53-58

Prescription of antiinfectives in patients treated by immunosuppressive therapy

Jan Strojil, Vladimíra Vojtová, Pavel Anzenbacher
Ústav farmakologie, Lékařská fakulta Univerzity Palackého v Olomouci

Introduction and aim: Patients on immunosuppression have an increased risk of infections and therefore also antiinfective utilization.

Our aim was to characterize the differences between these patients and individual immunosuppressants.

Methods: We analyzed prescription in the University Hospital Olomouc between 2005 and 2010, a total of 191,313 patients (average age

42 years, 51 % women), of whom 2,229 (1.2 %) fulfilled the criterion of at least 180 days of immunosuppressive treatment.

Results: Patients on immunosuppressive treatment received 10 % of all antiinfective DDDs and over 30 % of the total cost of antiinfective

drugs. The structure of prescription was significantly different with markedly higher use of cotrimoxazole (29 vs. 7 %, p < 0.01)

and fluoroquinolones. Prescription of combinations was twice as common (18 % vs. 9 %, p < 0.01) and the combinations were different

(amoxicillin and cotrimoxazole being the most common). On the other hand, incidence of repeated prescriptions or switches was lower.

Itraconazole was the most prescribed antifungal and valgalciclovir dominated antiviral prescription. Transplanted patients on tacrolimus

received significantly more antiinfectives than those on ciclosporine (5.5 vs. 3.2 DDD/100 days, p < 0.01).

Conclusions: Prescription patterns vary based on indication and immunosuppressant. Many antiinfective drugs pose a potential drugdrug

interaction risk and should be prescribed with caution and rationally.

Keywords: immunosuppression, antiinfective agents, antibiotics, defined daily dose, cyclosporine, tacrolimus

Published: June 20, 2011  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Strojil J, Vojtová V, Anzenbacher P. Prescription of antiinfectives in patients treated by immunosuppressive therapy. Klin Farmakol Farm. 2011;25(2):53-58.
Download citation

References

  1. Parasuraman R, Abouljoud M, Jacobsen G, et al. Increasing trend in infection-related death-censored graft failure in renal transplantation. Transplantation. 2011; 91(1): 94-99. Go to original source... Go to PubMed...
  2. Navarra SV, Leynes MS. Infections in systemic lupus erythematosus. Lupus. 2010; 19(12): 1419-1424. Go to original source... Go to PubMed...
  3. Rubin RH, Ikonen T, Gummert JF, et al. The therapeutic prescription for the organ transplant recipient: the linkage of immunosuppression and antimicrobial strategies. Transpl Infect Dis 1999; 1: 29. Go to original source... Go to PubMed...
  4. Tolkoff-Rubin NE, Rubin RH. Recent advances in the diagnosis and management of infection in the organ transplant recipient. Semin Nephrol 2000; 20: 148. Go to PubMed...
  5. WHO Collaborating Centre for Drug Statistics Mehodology: Anatomical Therapeutic Chemical (ATC) classification index including Defined Daily Doses (DDDs) for plain substances, 2009. http://www.whocc.no/.
  6. WHO Collaborating Centre for Drug Statistics Methodology: Guidelines for ATC classification and DDD assignment. World Health Organization, Oslo, 1996.
  7. Kořístková B, Grundmann M. Metodika studia spotřeb léků. Klin Farmakol Farm 2006; 20: 219-222.
  8. EBPG Expert Group on Renal Transplantation. European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.7.1 Late infections. Pneumocystis carinii pneumonia. Nephrol. Dial. Transplant. 2002; 17(Suppl 4): 36-39. Go to original source...
  9. Gupta D, Zachariah A, Roppelt H, Patel AM, Gruber BL. Prophylactic antibiotic usage for Pneumocystis jirovecii pneumonia in patients with systemic lupus erythematosus on cyclophosphamide: a survey of US rheumatologists and the review of literature.J Clin Rheumatol. 2008; 14(5): 267-272. Go to original source... Go to PubMed...
  10. Strojil J, Urbánek K, Anzenbacher P. Prescription of AntiInfective Drugs in Patients on Immunosuppression - Risk of Interactions. Pap Med Fac Univ Palacky Olomouc Czech Repub. 2010; 154(4): S1-S8. Go to original source...
  11. Ax F, Ekedahl A. Electronically transmitted prescriptions not picked up at pharmacies in Sweden. Res Social Adm Pharm. 2010; 6(1): 70-77. Go to original source... Go to PubMed...
  12. Luan FL, Kommareddi M. Ojo AO Universal prophylaxis is cost effective in cytomegalovirus serology-positive kidney transplant patients.Transplantation. 2011; 91(2): 237-244. Go to original source... Go to PubMed...
  13. Penninga L, M?ller CH, Gustafsson F, et al. Tacrolimus versus cyclosporine as primary immunosuppression after heart transplantation: systematic review with meta-analyses and trial sequential analyses of randomised trials. Eur J Clin Pharmacol. 2010; 66(12): 1177-1187. Go to original source... Go to PubMed...
  14. Treede H, Reichenspurner H, Meiser BM, et al. Incidence and spectrum of infections in lung transplanted patients: comparison of four different immunosuppressive protocols. Transplant Proc. 2001; 33(1-2): 1620-1621. Go to original source... Go to PubMed...
  15. Weimer R, Deisz S, Dietrich H, et al. Impact of maintenance immunosuppressive regimens - balance between graft protective suppression of immune functions and a near physiological immune response. Transpl Int. 2011; doi: 10.1111/j.14322277.2011.01241.x. Go to original source... Go to PubMed...




Clinical Pharmacology and Pharmacy

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.